Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Preferred Stock Liabilities (2016)

Historic Preferred Stock Liabilities for Voyager Therapeutics (VYGR) over the last 2 years, with Q4 2016 value amounting to $36.1 million.

  • Voyager Therapeutics' Preferred Stock Liabilities rose 12.76% to $36.1 million in Q4 2016 from the same period last year, while for Dec 2016 it was $36.1 million, marking a year-over-year increase of 12.76%. This contributed to the annual value of $36.1 million for FY2016, which is 12.76% up from last year.
  • Per Voyager Therapeutics' latest filing, its Preferred Stock Liabilities stood at $36.1 million for Q4 2016, which was up 12.76% from $36.1 million recorded in Q4 2015.
  • Over the past 5 years, Voyager Therapeutics' Preferred Stock Liabilities peaked at $89.0 million during Q3 2015, and registered a low of $36.1 million during Q4 2015.